Showing 1311-1320 of 3103 results for "".
- FDA Approves Diroximel Fumarate—A Second Generation Fumarate With Fewer Side Effects—for Treatment of Multiple Sclerosishttps://practicalneurology.com/news/fda-approves-diroximel-fumaratea-second-generation-fumarte-with-fewer-side-effectsfor-treatment-of-multiple-sclerosis/2469063/The Food and Drug Administration has approved diroximel fumarate (Vumerity; Biogen, Cambridge, MA and Alkermes, Dublin, Ireland) for the treatment of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing remitting MS (RRMS), and active secondary progressive MS (SPMS). &n
- Siponimod Approved by FDA for Treatment of Relapsing-Remitting and Secondary-Progressive Multiple Sclerosishttps://practicalneurology.com/news/siponimod-approved-by-fda-for-treatment-of-relapsing-remitting-and-secondary-progressive-multiple-sclerosis/2468792/The first drug to treat 3 phases of multiple sclerosis (MS), secondary-progressive MS (SPMS), relapsing-remitting MS (RRMS), and clinically isolated syndrome (CIS), has been approved by the Food and Drug Administration (FDA). Siponimod (Mayzent; Novartis, East Hanover, NJ) is an oral agent a
- In Memoriam: June Halper, MSN, APN-C, FAAN, MSCNhttps://practicalneurology.com/news/in-memoriam-june-halper-msn-apn-c-faan-mscn/2470537/June Halper, MSN, ASPN-C, FAAN, MSCN passed away on July 24, 2024, at age 86. Ms. Halper was a founding member of the Consortium of Multiple Sclerosis Centers (CMSC) and served as the organization’s President from 1995 to 1997 and as its Executive Director/CEO from 1992 until her death. Ms.
- Nanocrystalline Gold Provides Functional Improvements for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/nanocrystalline-gold-provides-functional-improvements-for-relapsing-multiple-sclerosis/2470004/In the VISIONARY-MS clinical trial (NCT03536559), participants with relapsing multiple sclerosis (MS) and optic neuritis (ON) treated with nanocrystalline gold (CNM-Au8; Clene Inc, Salt Lake City,
- Gastrointestinal Tolerability of Diroximel Fumarate May Shorten Time to Reach Optimal Dosehttps://practicalneurology.com/news/gastrointestinal-tolerability-of-diroximel-fumarate-may-shorten-time-to-reach-optimal-dose/2469719/In the phase 3 EVOLVE-MS-2 study (NCT03093324), individuals with relapsing multiple sclerosis (MS) treated with diroximel fumarate (Vumerity; Biogen, Cambridge, MA) (n=253) had improved gastrointestinal (GI) tolerability compared with
- Remembering Ronald DeVere, MD, FAANhttps://practicalneurology.com/news/remembering-ronald-devere-md-faan/2470936/Ronald DeVere, MD, FAAN, Practical Neurology Editorial Advisory Board member and former Editor of the Dementia Insights column, passed away on May 8, 2024, at age 80. Dr. DeVere served as the Director of the Taste & Smell Disorders Clinic and the Alzheimer Disease & Memory Disorder
- Study Assesses Biological Age Acceleration in People with Multiple Sclerosishttps://practicalneurology.com/news/study-assesses-biological-age-acceleration-in-people-with-multiple-sclerosis/2470415/Analysis of interim results from a study assessing biological aging in individuals with multiple sclerosis (MS) showed an increase in epigenetic age acceleration (EAA) in a subset of people with secondary progressive MS. The results were presented at the ninth annual Americas Committee for Treatm
- Ketogenic Diet May Reduce Disability and Improve Quality of Life in Multiple Sclerosishttps://practicalneurology.com/news/ketogenic-diet-may-reduce-disability-and-improve-quality-of-life-in-multiple-sclerosis/2469842/A preliminary study found that a ketogenic diet may be safe for people with multiple sclerosis (MS) and reduce fatigue, depression, and disability. Improved quality of life may also occur with a ketogenic diet for people with MS. During the study, 83% of participants adhered to a
- Interim Data Suggest Clinical Improvement Occurring With Nanocrystalline Gold Treatment of Multiple Sclerosishttps://practicalneurology.com/news/interim-data-suggest-clinical-improvement-occurring-with-nanocrystalline-gold-treatment-of-multiple-sclerosis/2469837/Updated interim data from 2 Phase 2 clinical trials support CNM-Au8, a catalytically active gold nanocrystal suspension, as a potential disease-modifying therapy for multiple sclerosis (MS). Data from the Phase 2 VISIONARY-MS study (NCT03536559) suggest treatment with nanocrystal
- Relapses in Multiple Sclerosis Significantly Increased Likelihood of Disability Worseninghttps://practicalneurology.com/news/relapses-in-multiple-sclerosis-significantly-increased-likelihood-of-disability-worsening/2469833/A new study published in Brain has revealed detailed information on how individuals with multiple sclerosis (MS) acquire disability. In retrospective analysis of observational and randomized controlled clinical trials that included over 27,000 individuals with MS, progression inde